RestorGenex Corp. (OTCQX: RESX) is a
specialty biopharmaceutical company focused on the development of a portfolio
of first-in-class therapeutic products to treat diseases across the oncologic,
ophthalmologic and dermatologic space. The company’s lead product candidate,
RES-529, is a novel PI3K/Akt/mTOR pathway inhibitor that has completed two
phase I clinical trials for the treatment of age-related macular degeneration
(AMD) and is in preclinical oncology development for the treatment of
glioblastoma multiforme (GBM). RestorGenex has announced plans to initiate
human clinical trials in GBM in 2016. Additionally, the company’s pipeline includes
RES-440, a ‘soft’ anti-androgen compound for the treatment of acne vulgaris.
Through its ongoing development
programs, RestorGenex is addressing a collection of underserved markets in the
biopharmaceutical industry. According to industry data, the worldwide market
for the treatment of GBM in 2013 was estimated at $1 billion, and that figure
is expected to climb to $4.5 billion by 2020. Due to the modest effectiveness
of currently available treatment options, this market performance could provide
an opportunity for RestorGenex to achieve considerable financial growth upon
commercialization of RES-529. The company’s innovative PI3K pathway inhibitor
has also shown promise in a number of additional indications, which RestorGenex
is currently evaluating for the purpose of creating safe and effective
treatments.
“The scientific research and
knowledge of RES-529 continues to expand, in particular for clinical oncology
applications,” Stephen M. Simes, chief executive officer of RestorGenex, stated
in a news release. “These new data help to validate our plans for future
studies with RES-529, as well as suggest that its analogs could also be
developed for oncology indications.”
Moving forward, RestorGenex will
lean on the strength of its balance sheet as it progresses toward the
commercialization of its promising development pipeline. As of June 30, 2015,
the company reported cash and cash equivalents of approximately $16.5 million,
which it expects to sufficiently fund its operations well into the second half of
2016. RestorGenex had no outstanding debt as of its latest financial filings.
For prospective shareholders, the
potential marketability of RestorGenex’s development pipeline, particularly in
oncology indications, could foreshadow an opportunity for the company to
achieve considerable market growth in the future. Look for the company to
continue benefitting from its favorable financial position as it advances its
product candidates in the months to come.
For more information, visit
www.restorgenex.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
